Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Dr. Reddy's To Manufacture Cellceutix Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News

Dr. Reddy’s To Manufacture Cellceutix Drug

Will make Prurisol for Phase II/III psoriasis trials

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cellceutix Corp. has selected Dr. Reddy’s Laboratories to manufacture Prurisol, its new drug candidate for the treatment of psoriasis. Dr. Reddy’s will manufacture Prurisol for oral dosing for Phase II/III trials, which will begin upon completion of the manufacturing.
 
“We have great expectations for this drug because it performed amazingly in lab studies. Our research showed Prurisol to be much more effective than methotrexate, a standard of care treatment for advanced psoriasis. We wanted to use only a world-class manufacturer and Dr. Reddy’s is internationally renowned for its excellence in research, manufacturing and distribution,” said Leo Ehrlich, chief executive officer at Cellceutix. “As we continue to emerge as a leading drug developer, we are committed to working with companies and organizations that have high standards and a strong reputation. Dr. Reddy’s is a perfect fit for Prurisol. Prurisol has a complex process for synthesizing and manufacturing in oral form and we are very pleased to have Dr. Reddy’s handling those formulations.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics